Production (Stage)
aTyr Pharma, Inc.
ATYR
$3.75
-$0.05-1.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -33.43% | -97.81% | -94.34% | -94.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -33.43% | -97.81% | -94.34% | -94.34% |
| Cost of Revenue | 14.14% | 28.56% | 23.51% | 14.58% | 6.90% |
| Gross Profit | -15.61% | -29.08% | -62.16% | -48.24% | -38.85% |
| SG&A Expenses | 8.80% | 6.15% | 1.42% | -10.40% | -5.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.96% | 23.30% | 18.45% | 8.49% | 3.77% |
| Operating Income | -14.09% | -23.66% | -45.07% | -30.84% | -25.54% |
| Income Before Tax | -17.59% | -27.04% | -47.86% | -28.48% | -19.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.59% | -27.04% | -47.86% | -28.48% | -19.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 33.33% | -112.50% | -111.11% | -112.50% | -40.00% |
| Net Income | -17.58% | -27.06% | -47.89% | -28.51% | -19.48% |
| EBIT | -14.09% | -23.66% | -45.07% | -30.84% | -25.54% |
| EBITDA | -14.25% | -23.71% | -44.97% | -30.26% | -24.68% |
| EPS Basic | 10.72% | 8.94% | 2.73% | 26.38% | 37.64% |
| Normalized Basic EPS | 10.72% | 8.94% | 2.72% | 26.38% | 37.64% |
| EPS Diluted | 10.72% | 8.94% | 2.73% | 26.38% | 37.64% |
| Normalized Diluted EPS | 10.72% | 8.94% | 2.72% | 26.38% | 37.64% |
| Average Basic Shares Outstanding | 33.11% | 38.61% | 48.57% | 65.04% | 86.61% |
| Average Diluted Shares Outstanding | 33.11% | 38.61% | 48.57% | 65.04% | 86.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |